HepaCAM联合吡柔比星抑制膀胱癌BIU-87细胞的增殖

吕长坤; 万雪莲; 马菲菲; 杜红飞; 杨 雪; 罗春丽

您当前的位置：

首页 >

文章列表页 >

HepaCAM联合吡柔比星抑制膀胱癌BIU-87细胞的增殖

骨科学2024神经精神疾病的治疗 | 更新时间：2023-12-18

- HepaCAM联合吡柔比星抑制膀胱癌BIU-87细胞的增殖
- Combined treatment of hepaCAM and pirarubicin inhibits the proliferation of bladder cancer BIU-87 cells
- 重庆医科大学学报 2015年40卷第2期页码：234-238
- 作者机构：
  
  1. 重庆医科大学检验医学院、临床检验诊断学教育部重点实验室,重庆,400016
  2. 商丘医学高等专科学校医学检验技术教研室,商丘,476100
- 作者简介：
- 基金信息：
- DOI：
  中图分类号：
- 纸质出版日期：2015，
扫描看全文
吕长坤, 万雪莲, 马菲菲, 等. HepaCAM联合吡柔比星抑制膀胱癌BIU-87细胞的增殖[J]. 重庆医科大学学报, 2015,40(2):234-238.

Lyu Changkun, Wan Xuelian, Ma Feifei, et al. Combined treatment of hepaCAM and pirarubicin inhibits the proliferation of bladder cancer BIU-87 cells[J]. Journal of Chongqing Medical University, 2015,40(2):234-238.
吕长坤, 万雪莲, 马菲菲, 等. HepaCAM联合吡柔比星抑制膀胱癌BIU-87细胞的增殖[J]. 重庆医科大学学报, 2015,40(2):234-238. DOI：

Lyu Changkun, Wan Xuelian, Ma Feifei, et al. Combined treatment of hepaCAM and pirarubicin inhibits the proliferation of bladder cancer BIU-87 cells[J]. Journal of Chongqing Medical University, 2015,40(2):234-238. DOI：

摘要

目的：研究肝细胞黏附分子（hepatocyte cell adhesion molecule，hepaCAM）联合吡柔比星（pirarubicin，THP）对膀胱癌细胞BIU-87的增殖影响。方法：将BIU-87细胞分为空白处理组、hepaCAM过表达腺病毒（adenovirus-GFP-hepaCAM，Ad-GFP-hepaCAM）处理组、THP处理组、Ad-GFP-hepaCAM联合THP处理组。噻唑蓝（methyl thiazolyl tetrazolium，MTT）检测细胞增殖，流式细胞仪（flow cytometry，FCM）检测细胞周期，real-time PCR检测细胞周期相关基因cyclinD1，CDK2的mRNA表达。将空白、空载腺病毒（adenovirus-GFP，Ad-GFP）、hepaCMA过表达腺病毒（Ad-GFP-hepaCAM）处理的BIU-87细胞分别注射于裸鼠皮下，观察裸鼠成瘤情况并记录瘤体体积，4周后处死裸鼠。切取各组瘤体组织，组织切片行HE染色和免疫组化检测hepaCAM蛋白的表达。结果：Ad-GFP-hepaCAM联合THP处理组，与THP处理组比较，BIU-87细胞增殖受到明显抑制（F=2.702，P=0.00）；细胞周期明显阻滞于G0/G1期（F=10.989，P=0.000）；cyclinD1、CDK2的mRNA 表达明显下调（F=5.4299，P=0.000）。Ad-GFP-hepaCAM处理组的BIU-87细胞成瘤体积明显低于空白处理组（F=12.587，P=0.000）。结论：hepaCAM基因能够增强吡柔比星对膀胱癌BIU-87细胞的增殖抑制作用。

Abstract

Objective：to investigate the effects of combination treatment of hepaCAM and pirarubicin（THP） on the proliferation of BI－U-87 cells. Methods：BIU-87 cells were designed as blank treatment group，adenovirus-GFP-hepaCAM treatment group（Ad-GFP-hepaCAM treatment group），THP treatment group，Ad-GFP-hepaCAM and THP combination treatment group. MTT was used to detect cell proliferation；cell cycle was evaluated by flow cytometry；the mRNA expressions of cyclinD1 and CDK2 were examined by re－al-time PCR. Cells that were designed as blank treatment group，Ad-GFP treatment group，Ad-GFP-hepaCAM treatment group were subcutaneously injected in nude mice. The volume of nude mice was evaluated. After 4 weeks，all mice were sacrificed，transplanted tumors were excised and tumor tissues were used to perform HE staining and immunohistochemistry was performed to examine hep－aCAM expression. Results：Ad-GFP-hepaCAM combined with THP exhibited more intense inhibitory effects on proliferation of BIU-87 cells than THP alone（F=2.702，P=0.000）. Meanwhile，the cell in G0/G1 was significantly increased（F=10.989，P=0.000） and mR－NA levels of cyclinD1 and CDK2 were significantly lowered in Ad-GFP-hepaCAM and THP combination treatment group than in THP group（F=5.4299，P=0.000）. In addition，the volume of tumors induced by hepaCAM-expression BIU-87 cells was significantly decreased compared with that of blank treatment group（F=12.587，P=0.000）. Conclusion：HepaCAM could enhance the inhibitory ef－fects of THP on the proliferation of bladder cancer BIU-87 cells.

关键词

HepaCAM吡柔比星膀胱癌cyclinD1CDK2

Keywords

hepaCAMpirarubicinbladder cancercyclinD1CDK2

references

浏览量

574

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

生物标志物炎症因子、细胞焦亡因子和铁死亡因子在膀胱癌治疗与预后中的价值

血清KLF5含量与阳性淋巴结比例的相关性及其对膀胱癌患者根治术后预后的预测价值

炎症标志物对肌层浸润性膀胱癌患者接受不同新辅助治疗方案疗效预测分析

造瘘口切口辅助技术在腹腔镜膀胱根治性切除及回肠通道术中的应用

膀胱全切不同尿流改道术后生活质量的比较